Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2340480 | 0.99 | PPARG (0.34) | PPARGHRH3ADRA1BADRA1DDRD2 | |
| SCHEMBL2345000 | 0.92 | MEN1 (0.35) | HRH3DRD2DRD3KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL2342696 | 0.91 | MEN1 (0.35) | HRH3DRD2DRD3KDM4EMAPT | |
| SCHEMBL2344978 | 0.85 | PPARG (0.38) | PPARGHRH3ADRA1BADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL2340476 | 0.84 | PPARG (0.38) | PPARGHRH3ADRA1BADRA1DDRD2 | |
| SCHEMBL2352078 | 0.80 | ADRA1D (0.39) | PPARGHRH3ADRA1BADRA1DPPARA | |
| SCHEMBL2344994 | 0.76 | MEN1 (0.37) | HRH3DRD2DRD3 | |
| SCHEMBL2345067 | 0.76 | HTR6 (0.40) | PPARGADRA1DPPARA | |
| Hydrochloric Acid SCHEMBL2342693 | 0.75 | MEN1 (0.36) | HRH3DRD2DRD3 | |
| SCHEMBL2349349 | 0.73 | REN (0.42) | PPARGPPARAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405300-B2 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMAVEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1663202-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | PARP1, PARP11, PARP3 | PPARG 3713/4885HRH3 889/4885ADRA1B 1084/4885 |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP11, PARP15 | PPARG 3500/4885HRH3 1035/4885ADRA1B 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.